Channel: Haloucinogen therapy

Hallucinogens are a large and diverse class of psychoactive drugs that can produce altered states of consciousness characterized by major alterations in thought, mood, and perception as well as other changes. Most hallucinogens can be categorized as either being psychedelics, dissociatives, or deliriants. Wikipedia (CC BY-SA 3.0)

2023 Articles

789 articles

Spatial Correspondence of LSD-Induced Variations on Brain Functioning at Rest With Serotonin Receptor Expression

  • Stefano Delli Pizzi, Piero Chiacchiaretta, Carlo Sestieri, …, David J Nutt, Robin L Carhart-Harris, Stefano L Sensi
  • Biol Psychiatry Cogn Neurosci Neuroimaging, 10.1016/j.bpsc.2023.03.009
Comment Section

Possible psychedelic therapeutic mechanism

  • Evan M Hess, Todd D Gould, Evan M Hess, …, Todd D Gould, Evan M Hess, Todd D Gould
  • Science, 10.1126/science.adg2989
Comment Section

Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders

  • Andreas B Wulff, Charles D Nichols, Scott M Thompson, …, Andreas B Wulff, Charles D Nichols, Scott M Thompson
  • Neuropharmacology, 10.1016/j.neuropharm.2023.109504
Comment Section

Psilocybin for the treatment of anorexia nervosa

  • Tomislav Majić, Tomislav Majić, Tomislav Majić, Stefan Ehrlich, Tomislav Majić, Stefan Ehrlich
  • Nat Med, 10.1038/s41591-023-02458-6
Comment Section

Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling

  • Jing Wang, Min Liang, Qing Shang, …, Gaojie Shao, Tao Li, Xinshe Liu
  • CNS Neurosci Ther, 10.1111/cns.14054
Comment Section

Acute psilocybin enhances cognitive flexibility in rats

  • Randall J Olson, Gabriela Garza, Bita Moghaddam, …, Randall J Olson, Gabriela Garza, Bita Moghaddam
  • Neuropsychopharmacology, 10.1038/s41386-023-01545-z
Comment Section

Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans

  • Flora Moujaes, Katrin H Preller, Jie Lisa Ji, …, Lucie Berkovitch, Franz X Vollenweider, Alan Anticevic
  • Biol Psychiatry, 10.1016/j.biopsych.2022.10.021
Comment Section

Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding

Comment Section

Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity

Comment Section

Psychedelic therapy in the treatment of addiction: the past, present and future

  • Rayyan Zafar, Maxim Siegel, Rebecca Harding, …, Matthew Wall, David John Nutt, David Erritzoe
  • None, 10.3389/fpsyt.2023.1183740
Comment Section

2022 Articles

100 articles

Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis

  • Ricardo Irizarry, Amelia Winczura, Omar Dimassi, …, Navpreet Dhillon, Annu Minhas, Jeanpaul Larice
  • None, 10.7759/cureus.31796
Comment Section

A unified model of ketamine’s dissociative and psychedelic properties

  • Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues, …, Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues
  • J Psychopharmacol, 10.1177/02698811221140011
Comment Section

Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines

Comment Section

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms

  • Juliet Meccia, Joëlle Lopez, Rosemary C Bagot, …, Juliet Meccia, Joëlle Lopez, Rosemary C Bagot
  • Psychopharmacology (Berl), 10.1007/s00213-022-06297-0
Comment Section

(+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission

  • Hugo R Arias, Philippe De Deurwaerdère, Ali El-Kasaby, …, Junho H Lee, Michael Freissmuth, Abdeslam Chagraoui
  • Eur J Pharmacol, 10.1016/j.ejphar.2022.175454
Comment Section

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

  • Benjamin Kelmendi, Stephen A Kichuk, Giuliana DePalmer, …, Terence H W Ching, Alexander Belser, Christopher Pittenger
  • None, 10.1016/j.heliyon.2022.e12135
Comment Section

Effect of psilocybin on decision-making and motivation in the healthy rat

  • Brianna F Roberts, Alexia L Zylko, Courtney E Waters, …, Abhishek K Sen, J Andrew Jones, Matthew S McMurray
  • Behav Brain Res, 10.1016/j.bbr.2022.114262
Comment Section

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants

  • Friederike Holze, Anna M Becker, Karolina E Kolaczynska, …, Karolina E Kolaczynska, Urs Duthaler, Matthias E Liechti
  • Clin Pharmacol Ther, 10.1002/cpt.2821
Comment Section

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation

  • Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo, …, Jens D Mikkelsen, Gitte Moos Knudsen, Patrick MacDonald Fisher
  • Psychoneuroendocrinology, 10.1016/j.cpnec.2022.100163
Comment Section

Moderators of ayahuasca’s biological antidepressant action

  • Geovan Menezes de Sousa, Vagner Deuel de Oliveira Tavares, Ana Cecília de Menezes Galvão, …, Jerome Sarris, Dráulio Barros de Araujo, Nicole Leite Galvão-Coelho
  • None, 10.3389/fpsyt.2022.1033816
Comment Section